We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Expert Opinion / Cases · April 16, 2021

Adenocarcinoma of Prostate Gleason 5+5

Written by
Pedro C. Barata MD


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Waleed Ragab


  • Kenneth Chen

    The presence of a BRCA2 mutation tells us he would benefit from the PARPI, however indication is only in the mCRPC space. I would offer docetaxel for this patient based on the aggressive histology, high volume disease including viscera involvement and considering his good performance status.

  • Jose Luis Soto Rodriguez

    docetaxel x6 cycles

  • Hadi Molana


  • Muho Ahmed


  • Rene Henriquez

    Docetaxel 6cycles

  • Thomas Zahreddin


  • Kazuyuki Sagiyama

    Docetaxel 6cycles

  • Bahram Mofid


  • Luis Barreras

    Use docetaxel

  • Abdelhamid Sabaa

    Both Enzalutamide and Arbiraterone + Prednisolone are suitable alternatives. I would suggest keeping the Docetaxel for relapses

  • Sava Micic

    Docetaxel 6 cycles

  • Oscar Londono


  • Charles Maack

    Enzalutamide (Xtandi), but if not effective, olaparib (Lynparza) or rucaparib (Rubraca), and if still not effective, docetaxel plus carboplatin x6 cycles. If all not effective but patient still mobile, possibly pembrolizumab (Keytruda).

  • John Ochai

    Docetaxel 6 cycles The patient is young and with good performance status so should be offered upfront Docetaxel chemotherapy

  • Saad Benjelloun


  • emine sevil bavbek

    Docetaxel 6 cycles. Tempted to add platinum with the BRCA mutation, but no data in the HAPC setting

  • Luis Felipe Lara Moscoloni

    1 enzalutamide 2 olaparib 3 docetaxel

  • Charles Maack

    Two research comments: Germline BRCA2 carriers who received first-line abiraterone or enzalutamide (Xtandi, Astellas) vs. taxanes had longer cause-specific survival (24 months vs. 17 months) and PFS2 (18.9 months vs. 8.6 months). Patients with metastatic castration-resistant prostate cancer and harboring germline mutations in BRCA1/2 and ATM benefit from treatment with abiraterone and enzalutamide

  • Charles Maack

    In any event, a prognosis for a patient with the status identified is, unfortunately, not good despite the good intentions of suggested therapies.

  • Syamsu Hudaya

    Docetaxel 6x

  • farhood khaleghi mehr


  • Antonio Rosino-Sánchez

    apalutamide or enzalutamide. Chemo after progression (docetaxel plus platin based). Olaparib if progression after chemo

  • Manuel Ossa

    doxetacel x 6 cycles

  • Khoury Elie


  • Rosanna Mirabelli

    docetaxel (alto rischio alto volume)

  • Oliver Sartor

    More clinical trial clearly needed in this space....one day we may add a PARP inhibitor. The ADT + "novel hormones" gives a better PFS than ADT + docetaxel.....buying more time until progression allows to be more creative in the future. This patient may respond well to DNA damaging agents like Lu-177 tagged to PSA targeting agents. Would be great to get the trial open with ADT + novel hormone +/- PSMA Lu-177

  • Charles Maack

    Dr. Sartor’s recommendation for Lutetium-177 PSMA is certainly one of the best approaches in this case once approved by the FDA. Currently, this treatment is only approved for use in Germany, with a few other countries prescribing as a novel treatment option. So far with Phase III of the VISION trial, the intermediate results demonstrate that Lutetium-177 PSMA therapy leads to a significant improvement in biochemical and radiological parameters, improves the quality and general life expectancy of patients with metastatic prostate cancer. According to statistics obtained during the relevant international VISION and LuPSMA trials, the use of Lutetium-177 leads to a significant improvement in the results of laboratory tests and PET-CT (more than 57% of patients), and also improves quality (more than 70% of patients) and expectancy of life (more than 45% of patients).

  • Jun 20, 2021

    Pending Moderator approval.

Further Reading